INTRAVENOUS POTASSIUM CHLORIDE: HOSPITALWIDE EVALUATION AND BENEFITS OF A VIDEO COURSE
5PSQ-008
ASSESSMENT OF PATIENTCONTROLLED ANALGESIA (PCA) PRACTICES IN A PUBLIC HOSPITAL
5PSQ-123
ORPHAN OFF-LABEL DRUG: IS IT REALLY COMMON PRACTICE?
5PSQ-110
OMEPRAZOLE DEPRESCRIPTION PROJECT IN A SOCIAL HEALTH CENTER WITH A DEPOSIT OF MEDICINES ASSOCIATED WITH A HOSPITAL PHARMACY SERVICE
5PSQ-098
EXPERIENCE IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION
5PSQ-080
ERTAPENEM-INDUCED NEUROTOXICITY: ROLE OF PLASMA CONCENTRATION MONITORING
5PSQ-069
DOES THE TREATMENT LINE HAVE AN IMPACT ON THE TOXICITY PRODUCED BY OFF-LABEL ONCOLOGICAL TREATMENTS?
5PSQ-056
LOT QUALITY ASSURANCE SAMPLING (LQAS) OF A TELEPHARMACY PROGRAMME FROM THE HOSPITAL PHARMACY TO THE OUTPATIENT THROUGH THE COMMUNITY PHARMACY
5PSQ-049
STARTING POINT TO PROMOTE A POTENTIALLY INAPPROPRIATE PRESCRIPTION ASSESSMENT PROJECT
5PSQ-026
CLINICAL IMPORTANCE OF GENETIC VARIANTS IN CAPECITABINE BIOACTIVATION PATHWAY FOR THE PREDICTION OF RESPONSE IN COLORECTAL CANCER PATIENTS
5PSQ-025
ANTICHOLINERGIC RISK IN OLDER PEOPLE LIVING WITH HIV
5PSQ-003
DEVELOPMENT AND APPLICABILITY OF THE MEDHIPPRO-Q: A QUESTIONNAIRE ASSESSING MEDICAL DOCTORS’ EXPERIENCE WITH MEDICATION MANAGEMENT IN THE HIP FRACTURE PATIENT PATHWAY
5PSQ-042
TOXICITY OF REMDESIVIR AS TREATMENT OF NON-CRITICALLY ILL COVID-19 PATIENTS
5PSQ-034
HOMOGENEITY OF OPINION EXPERT ON CLEO SCALE WHEN APPLIED TO 50 MODELED PHARMACEUTICAL INTERVENTIONS
5PSQ-157
SEVERE NEUROTOXICITY OF ORAL IVERMECTIN: A SYSTEMATIC REVIEW OF CASES AND CASE SERIES
